SCHEMBL459834

SCHEMBL459834

N#Cc1cc(Br)cnc1O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
EGFR P00533 3/20 0.35
ERBB2 P04626 2/20 0.35
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
HTT P42858 2/20 0.34
TTR P02766 1/20 0.34
ALB P02768 1/20 0.34
POLB P06746 1/20 0.33
HPGD P15428 1/20 0.33
XDH P47989 1/20 0.33
ABL1 P00519 1/20 0.32
KDR P35968 1/20 0.32
MAOA P21397 2/20 0.32
MAOB P27338 2/20 0.32
PTGES O14684 1/20 0.31
S1PR1 P21453 1/20 0.31
S1PR3 Q99500 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13852138 0.79 HTT (0.34) KMT2AHTTPLAU
SCHEMBL30217691 0.75 HTT (0.54) CHEK1CYP11B1CYP11B2KMT2AMEN1
SCHEMBL17486279 0.75 CYP11B2 (0.37) CHEK1CYP11B1CYP11B2KMT2AMEN1
SCHEMBL29904603 0.75 ALDH1A1 (0.53) CHEK1CYP11B1CYP11B2KMT2AHTT
SCHEMBL322329 0.75 HTT (0.54) CHEK1CYP11B1CYP11B2KMT2AMEN1
SCHEMBL30259596 0.75 CYP11B2 (0.44) CHEK1CYP11B1CYP11B2KMT2AMEN1
SCHEMBL31200432 0.75 CHRNB2 (0.40) CHEK1CYP11B1CYP11B2EGFRERBB2
SCHEMBL1164261 0.75 ALDH1A1 (0.53) CHEK1CYP11B1CYP11B2KMT2AHTT
SCHEMBL29658015 0.75 CYP11B2 (0.37) CHEK1CYP11B1CYP11B2KMT2AMEN1
SCHEMBL17403581 0.75 CHRNB2 (0.40) CHEK1CYP11B1CYP11B2EGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025021182-A1 CYP11A1 INHIBITORS ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) 2025-01-30 WO disclosed
US-20240360131-A1 BIARYL KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2024-10-31 US disclosed
US-12065437-B2 Biaryl kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-20 US disclosed
US-20230295076-A1 ACETOPHENONE OXIME COMPOUND AND APPLICATION THEREOF MEDSHINE DISCOVERY INC. (CN) 2023-09-21 US disclosed
EP-4116295-A1 TRICYCLIC COMPOUNDS AND USE THEREOF HELIOEAST PHARMACEUTICAL CO., LTD. (CN) 2023-01-11 EP disclosed
US-20210277001-A1 BIARYL KINASE INHIBITORS Cosmic Pet LLC 2021-09-09 US disclosed
EP-3828184-A1 PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF AS PI3K INHIBITOR Medshine Discovery Inc. (CN) 2021-06-02 EP disclosed
US-10981910-B2 Biaryl kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2021-04-20 US disclosed
CN-112142655-A Biaryl kinase inhibitors 百时美施贵宝公司 2020-12-29 CN disclosed
EP-3191467-B1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS NOVARTIS AG (CH) 2020-10-21 EP disclosed
US-20170183340-A1 BIARYL KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-06-29 US disclosed
EP-3126351-A1 BIARYL KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2017-02-08 EP disclosed
WO-2016038583-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS NOVARTIS AG (CH) 2016-03-17 WO disclosed
WO-2015153720-A1 BIARYL KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2015-10-08 WO disclosed
EP-2102189-B1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-07-29 EP disclosed
US-8410155-B2 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-02 US disclosed
WO-2011147951-A1 CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS PROSIDION LIMITED (GB) 2011-12-01 WO disclosed
US-20100016316-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-01-21 US disclosed
EP-2102189-A2 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS Brystol-Myers Squibb Company (US) 2009-09-23 EP disclosed
WO-2008076805-A2 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10981910-B2 Biaryl kinase inhibitors AAK1, NCK1, MARCKS CHEK1 195/4885CYP11B1 3461/4885CYP11B2 3752/4885
US-20230295076-A1 ACETOPHENONE OXIME COMPOUND AND APPLICATION THEREOF CYP11B2, ALDH7A1, CYP11B1 CHEK1 3484/4885CYP11B1 3/4885CYP11B2 1/4885
US-20100016316-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS F12, TFPI, F11 CHEK1 3032/4885CYP11B1 3971/4885CYP11B2 3998/4885
US-20210277001-A1 BIARYL KINASE INHIBITORS AAK1, NCK1, MARCKS CHEK1 195/4885CYP11B1 3461/4885CYP11B2 3752/4885
US-20170183340-A1 BIARYL KINASE INHIBITORS AAK1, NCK1, MARCKS CHEK1 195/4885CYP11B1 3461/4885CYP11B2 3752/4885
US-12065437-B2 Biaryl kinase inhibitors AAK1, NCK1, MARCKS CHEK1 195/4885CYP11B1 3461/4885CYP11B2 3752/4885
US-20240360131-A1 BIARYL KINASE INHIBITORS AAK1, NCK1, MARCKS CHEK1 195/4885CYP11B1 3461/4885CYP11B2 3752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.